A nurse is caring for a client who has been taking sumatriptan for several months. Which of the following statements by the client indicates a therapeutic response to the medication?

Sumatriptan is a selective serotonin receptor agonist (triptan) that targets 5-HT1B and 5-HT1D receptors to cause cranial vasoconstriction. It effectively inhibits the release of pro-inflammatory neuropeptides and suppresses pain transmission within the trigeminal vascular system. Rationale: A. Reduction in hand tremors is not a therapeutic effect of sumatriptan, which is specific to migraine pathology. Tremors are usually managed with beta-blockers or dopaminergic agents. Sumatriptan does not influence the motor pathways of the central nervous system or the extrapyramidal system to decrease involuntary muscle movements or tremors in patients. B. Improved skin condition or the reduction of acne breakouts is unrelated to the pharmacological action of sumatriptan. Triptans do not possess antimicrobial or hormonal properties that would affect the sebaceous glands or integumentary system. This statement would indicate a response to dermatological treatments rather than a medication used for acute migraine relief. C. The statement that migraine headaches are shorter in duration indicates a therapeutic response, as sumatriptan is used for the acute treatment of migraine attacks. By stimulating serotonin receptors, it reverses the vasodilation and perivascular inflammation responsible for the throbbing pain. Success is measured by the rapid relief of pain and associated symptoms like photophobia. D. Arthritis pain relief is not an effect of sumatriptan because it is not a general analgesic or anti-inflammatory agent like NSAIDs. Sumatriptan specifically targets receptors found in the cranial blood vessels and has no affinity for peripheral joints or musculoskeletal tissues. It would be ineffective in managing chronic joint inflammation or systemic arthritic pain.